Fluticasone Propionate/Salmeterol (Seretide 250 Accuhaler)
Is It Right for You?
A complete guide to Fluticasone Propionate/Salmeterol (Seretide 250 Accuhaler) — what it treats, how it works, dosages, side effects, and when a clinician may prescribe it following an online consultation.
What Is Seretide 250 Accuhaler?
Seretide 250 Accuhaler is a breath-actuated dry powder inhaler (DPI) delivering fluticasone propionate 250 micrograms and salmeterol 50 micrograms per blister inhalation. It represents a high-dose ICS/LABA combination — delivering fluticasone 500 mcg/day at the standard twice-daily dosing regimen — and is positioned for patients with asthma requiring high-dose ICS alongside LABA therapy, or for patients with COPD who benefit from this specific ICS/LABA combination.
The Accuhaler is a multi-dose DPI device that does not require hand-breath coordination (unlike pMDI Evohalers), making it suitable for patients who find pressurised inhaler coordination difficult. The device is breath-actuated — inserting the mouthpiece and inhaling forcefully activates the mechanism. Each Accuhaler contains 60 blisters of pre-dispensed drug, with a dose counter to track remaining doses.
Seretide 250 Accuhaler is a prescription-only medication in the UK.
What Conditions Is Seretide 250 Accuhaler Used For?
Seretide is indicated for:
for patients with moderate-to-severe asthma whose symptoms are not adequately controlled on medium-dose ICS, or where high-dose ICS plus LABA combination is clinically indicated
maintenance treatment of patients with COPD (FEV1 <60% predicted) with a history of repeated exacerbations; Seretide 250 Accuhaler is one of the licensed options for COPD ICS/LABA maintenance
for patients whose asthma requires escalation to higher ICS doses while maintaining LABA therapy
Fluticasone propionate 250 mcg per inhalation (500 mcg/day at standard dosing) represents a high-dose ICS regimen. The adrenal suppression, skin bruising, bone mineral density, and HPA axis risks associated with high-dose ICS are proportionally greater with fluticasone propionate than with other ICS agents at equivalent doses due to its higher potency. Patients on high-dose fluticasone should carry a steroid warning card and receive bone health and adrenal suppression monitoring as part of their long-term management.
How Does Seretide 250 Accuhaler Work?
The mechanism of action is identical to all fluticasone/salmeterol combinations — please refer to the Seretide 125 Evohaler section above for the detailed mechanistic description of both fluticasone propionate (ICS) and salmeterol (LABA). The Seretide 250 Accuhaler delivers a higher dose of fluticasone per inhalation, providing greater airway anti-inflammatory suppression appropriate for patients requiring high-dose ICS therapy.
Key pharmacokinetic distinction of DPI vs. pMDI delivery: The Accuhaler's dry powder formulation does not use propellants. Drug deposition in the lungs is dependent on the patient's peak inspiratory flow (PIF) — patients must inhale forcefully and deeply for optimal drug delivery. This contrasts with pMDI Evohalers, which deliver drug via propellant pressure regardless of inspiratory effort. In patients with severely obstructed airways or very low inspiratory flow (e.g., severe COPD exacerbations), DPI delivery may be less reliable than pMDI delivery via spacer.
Dosages & Administration
The correct dose depends on the type and severity of infection, age, weight, and kidney function. Always follow your clinician's instructions. The table below is for general reference only.
Administration Tips
Load the Accuhaler correctly before each inhalation. Open the outer case, slide the lever away until it clicks — this loads one blister. The dose counter decrements with each loaded dose.
Do not shake the Accuhaler. Unlike pMDI inhalers, shaking a DPI is not required and may dislodge the powder from the blister before inhalation.
Inhale forcefully and deeply. Exhale fully away from the inhaler (not into the device), seal your lips around the mouthpiece, and inhale quickly and deeply. Hold breath for 10 seconds. The forceful inhalation draws the powder deep into the airways.
Rinse mouth and gargle with water after every dose — spit, do not swallow. Essential to prevent oral candidiasis and dysphonia from fluticasone deposition.
Do not exhale into the device — moisture from breath can clump the powder and clog the mechanism.
Keep the Accuhaler dry and store in a cool, dry place.
Side Effects of Seretide 250 Accuhaler
Most side effects are mild and resolve on their own. Serious side effects are rare but require immediate medical attention.
- Oral candidiasis and dysphonia --- as with all ICS inhalers; preventable with mouth rinsing
- Palpitations and tremor --- beta-2 agonist effects of salmeterol
- Headache
- Bruising of skin (ecchymosis) --- from systemic fluticasone effects at high doses; more common at fluticasone 500 mcg/day than at lower doses
- Adrenal suppression --- greater risk at high-dose fluticasone; steroid warning card is mandatory for patients on high-dose ICS
- Reduced bone mineral density --- increased fracture risk with prolonged high-dose ICS; baseline and serial DEXA scanning recommended
- Growth retardation in children --- relevant if used in children; regular height monitoring required
Patients on Seretide 250 Accuhaler (fluticasone 500 mcg/day) must carry a steroid warning card due to the risk of adrenal suppression. Bone mineral density monitoring (baseline DEXA scan), annual review of total ICS dose, and assessment of skin fragility and bruising are part of the required long-term safety monitoring for patients on high-dose ICS regimens.
Drug Interactions
Always disclose all prescription drugs, over-the-counter medicines, vitamins, and supplements to your clinician or pharmacist before starting Seretide 250 Accuhaler
the risk of systemic corticosteroid effects (Cushing's syndrome, adrenal suppression) is proportionally greater with higher-dose inhaled fluticasone; this combination must be avoided unless no alternative exists.
Important Warnings
The Accuhaler requires a minimum peak inspiratory flow for effective drug delivery. In patients with severely obstructed airways or during acute exacerbations with very low inspiratory capacity, a pMDI with spacer may deliver drug more reliably. Inhaler technique and inspiratory flow should be assessed at initiation and periodically thereafter.
Speak to a Clinician About Treatment
Getting advice no longer means sitting in a waiting room. Through The GP Service, you can consult with a licensed clinician in minutes — from home, on your lunch break, or wherever works for you. If treatment is clinically appropriate, your clinician can issue a prescription during the consultation. A consultation does not guarantee a prescription.
The treatment you need, when you need it.
Seretide 250 Accuhaler FAQs
Slide the lever on the Accuhaler away from you until it clicks fully — this opens and loads one blister. The dose counter will show the number of doses remaining. Do not click the lever multiple times; this wastes doses. Each click loads exactly one dose.
Yes — DPI preparations deliver a very fine powder with little or no perceptible taste or sensation at therapeutic doses. The absence of sensation does not indicate device malfunction. If the dose counter is decrementing with each use and your inhaler technique is correct (forceful, deep inhalation), you are receiving the dose.
The Accuhaler does not require hand-breath coordination — the act of forceful inhalation alone delivers the drug. This makes it more reliable for patients who find it difficult to simultaneously press an MDI canister and inhale. It also avoids the need for a spacer device. However, it requires adequate inspiratory flow, which may be a limitation in patients with very severe airflow obstruction.
A steroid warning card alerts medical staff that you are taking inhaled corticosteroids at a dose sufficient to potentially suppress your adrenal glands. During periods of severe physiological stress — such as major surgery, serious illness, or significant trauma — your body may not be able to produce sufficient cortisol. Medical teams need to know this so they can provide additional steroid cover if necessary. Carry the card at all times and present it to any healthcare professional treating you in an emergency.
Prolonged high-dose ICS therapy — particularly fluticasone at 500 mcg/day or more — is associated with reduced bone mineral density. Your clinician may recommend a baseline DEXA scan and follow-up scans as part of your long-term management, particularly if you have additional osteoporosis risk factors. Calcium and vitamin D supplementation should also be considered. Discuss bone health monitoring at your next review appointment.